Allergy & Immunology

Developed Formulas
Benefits
  • Promotes a healthy response to viral infections

  • Supports healthy immunity

  • Anti-pathogenic activity

  • Supports intestinal membrane integrity

Allergy & Immunology
Ready to market
Allergy & Immunology
Clinical test
Allergy & Immunology
Microbac
Allergy & Immunology
In vitro test
Allergy & Immunology
Hydrosoluble powder
Allergy & Immunology
Allergen Free
Allergy & Immunology
Real time stability
Components

Lactiplantibacillus plantarum LP01 (LMG P-21021)
Lactiplantibacillus plantarum LP02 (LMG P-21020)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
Lacticaseibacillus rhamnosusLR05 (DSM 19739)
Bifidobacterium lactis BS01 (LMG P-21384)
Fructooligosaccharides (FOS)

Label Claim
Effective nutraceutical combination
Scientific Rationale

BIFIVIR® is a potent probiotic product designed to deliver high-potency strains that support the immune system, counteract pathogens, and combat oxidative stress and inflammation [1-4]. The five strains in BIFIVIR® strengthen immune defenses and optimize their protective function due to their unique properties:

  • Immunomodulation, including the ability to stimulate dendritic cell differentiation, activate natural killer cells, and increase IFNα and IFNγ secretion while decreasing IL-6.

  • Anti-pathogenic activity, effective against respiratory infections like Klebsiella pneumoniae and Pseudomonas aeruginosa, and protection of gut membrane integrity against external pathogens.

BIFIVIR® has undergone clinical studies for preventing winter diseases. In the first clinical study [6], 90 days of BIFIVIR® administration significantly reduced the prevalence, severity, and duration of flu episodes, upper respiratory tract infections, and acute respiratory infections, often by half. In the second clinical study [7], BIFIVIR® was tested alongside colostrum [6] to assess its effectiveness in preventing flu episodes compared to vaccination. During 8 weeks of supplementation and a 9-week follow-up, the group receiving both immunomodulators (BIFIVIR®+colostrum) had fewer flu episodes with reduced severity and fewer sick days. This approach also cut treatment and lost workdays costs in half.

Bibliography

1. Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.doi: 10.1097/MCG.0000000000001068

2. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7

3. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.  DOI: 10.35248/2329-8901.20.8.216

4. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214.

5. Internal Probiotical Data

6. Pregliasco F., et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.  Doi 10.1097/MCG.0b013e31817e1c91

7. Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.

Associations